Aerie Pharma Shares Skyrocket On Glaucoma Drug Study Results

By Wallace WitkowskiMarketWatch Pulse

Aerie Pharmaceuticals Inc. shares skyrocketed late Wednesday after the drug developer said its glaucoma treatment met its primary endpoint in a late-stage clinical trial. Aerie shares surged 70% to $30.59 on heavy volume. The company said its glaucoma treatment Rhopressa worked just as well as another treatment, timolol. Aerie said it expects to file a marketing application for Rhopressa with the Food and Drug Administration in mid-2016.

Copyright © 2015 MarketWatch, Inc.

Continue Reading Below